Prevalence of oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal cancer in Iran

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 17, 2015, Pages 7603-7606

  Shahriari Ahmadi, Ali ^a   Fahimi, Ali ^a   Payandeh, Mehrdad ^b   Sadeghi, Masoud ^c  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anemia; Chronic neuropathy; Colorectal cancer; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLATINUM COMPLEX;

ANALOGS AND DERIVATIVES; ANEMIA; BODY MASS; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; FEMALE; HUMAN; HYPERCALCIURIA; IRAN; KIDNEY CALCIFICATION; KIDNEY TUBULE DISORDER; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK FACTOR;

ANEMIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; HYPERCALCIURIA; IRAN; LEUCOVORIN; MALE; MIDDLE AGED; NEPHROCALCINOSIS; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; RENAL TUBULAR TRANSPORT, INBORN ERRORS; RISK FACTORS;

EID: 84949895392     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.17.7603     Document Type: Article

References (25)

1. Alejandro LM, Behrendt CE, Chen K, Openshaw H, Shibata S (2013). Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol, 36, 331-7.
2. André T, Boni C, Mounedji-Boudiaf L, et al (2004). Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350, 2343-51.
3. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012). Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol, 82, 51-77.
4. Argyriou AA, Polychronopoulos P, Iconomou G, et al (2007). Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol, 46, 1131-7.
5. Argyriou AA, Zolota V, Kyriakopoulou O, Kalofonos HP (2010). Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents. J BUON, 15, 435-46.
6. Azadeh S, Moghimi-Dehkordi B, Fatem SR, et al (2008). Colorectal cancer in Iran: an epidemiological study. Asian Pac J Cancer Prev, 9, 123-6.
7. Baek KK, Lee J, Park SH, et al (2010). Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat, 42, 185-90.
8. Cassidy J, Clarke S, Díaz-Rubio E, et al (2011). XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cance, 105, 58-64.
9. Cassidy J, Tabernero J, Twelves C, et al (2004). XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol, 22, 2084-91.
10. Cersosimo RJ (2005). Oxaliplatin-associated neuropathy: a review. The Annals of Pharmacology, 39, 128-35.
11. Chau I, Cunningham D (2006). Adjuvant therapy in colon cancer-what, when and how? Ann Oncol, 17, 1347-59.
12. de Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47.
13. Gamelin L, Boisdron-Celle M, Delva R, et al (2004). Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res, 10, 4055-61.
14. Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002). Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol, 29, 21-33.
15. Kalofonos HP, Aravantinos G, Kosmidis P, et al (2005). Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol, 16, 869-77.
16. Kono T, Satomi M, Asama T, et al (2010). Cetuximab-induced hypomagnesaemia aggravates peripheral sensory neurotoxicity caused by oxaliplatin. J Gastrointest Oncol, 1, 97-101.
17. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al (2004). Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol, 22, 648-57.
18. Park SB, Goldstein D, Lin CS, et al (2009). Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol, 27, 1243-9.
19. Payandeh M, Sadeghi M, Sadeghi E, Gholami F (2015). Analysis of KRAS, BRAF and NRAS in Patients with Colorectal Cancer: the First Report of Western Iran. Am J Cancer Prev, 3, 19-22.
20. Rothenberg ML, Cox JV, Butts C, et al (2008). Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol, 19, 1720-6.
21. Saif MW, Wilson RH, Harold N, et al (2001). Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs, 12, 525-31.
22. Sittl R, Lampert A, Huth T, et al (2012). Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A, 109, 6704-9.
23. Stone WL, Krishnan K, Campbell SE, et al (2004). Tocopherols and the treatment of colon cancer. Ann NY Acad Sci, 1031, 223-33.
24. Storey DJ, Sakala M, McLean CM, et al (2010). Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy? Ann Oncol, 21, 1657-61.
25. Vincenzi B, Frezza AM, Schiavon G, et al (2013). Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer, 21, 1313-9.